Medicine Department, University of the Region of Joinville (Univille), Rua Rio do Sul 270, Joinville, Santa Catarina, 89202-201, Brazil.
Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Int Urol Nephrol. 2024 Sep;56(9):3013-3022. doi: 10.1007/s11255-024-04018-4. Epub 2024 Apr 5.
Brazil has one of the world's highest numbers of patients on hemodialysis (HD). Most dialysis centers are private and perform HD for patients with private and public health insurance. We compared 1-year survival between patients initiating chronic HD with public and private health insurance.
This is an HD register-based retrospective cohort. Adult patients starting HD from January 2011 to December 2021 were included. Survival analysis was stratified according to the period entered in the HD register. Multivariate Cox regression focused on 1-year survival differences between private and public patients.
In the final sample (n = 5114), 68.5% of participants had public and 31.3% to private health insurance, with overall 1-year survival of 92.8% and 89.9%, respectively (p = 0.002). Crude analysis showed a slightly higher survival rate among patients with public health insurance than those with private health insurance (91 vs. 87%, p = 0.030) in the first period (2019-21). However, the adjusted hazard ratio (HR) did not remain significantly higher for patients with private health insurance compared to those with public health insurance (HR = 1.07; 95% CI 0.80-1.41; p = 0.651), even after propensity score matching of the groups by several baseline features.
Brazilian chronic HD patients funded by either private health plans or the public system have a similar 1-year mortality risk after controlling for several sociodemographic and clinical parameters.
巴西是世界上接受血液透析(HD)治疗的患者人数最多的国家之一。大多数透析中心是私营的,为有私人和公共医疗保险的患者提供 HD 治疗。我们比较了使用私人和公共医疗保险开始慢性 HD 治疗的患者的 1 年生存率。
这是一项基于 HD 登记的回顾性队列研究。纳入 2011 年 1 月至 2021 年 12 月期间开始接受 HD 治疗的成年患者。生存分析根据患者进入 HD 登记的时期进行分层。多变量 Cox 回归侧重于私人和公共患者之间 1 年生存率的差异。
在最终样本(n=5114)中,68.5%的参与者有公共医疗保险,31.3%的参与者有私人医疗保险,总体 1 年生存率分别为 92.8%和 89.9%(p=0.002)。在第一时期(2019-21 年),未经调整的分析显示,公共医疗保险患者的生存率略高于私人医疗保险患者(91%比 87%,p=0.030)。然而,调整后的风险比(HR)对于私人医疗保险患者与公共医疗保险患者相比并不显著更高(HR=1.07;95%CI 0.80-1.41;p=0.651),即使在通过几个基线特征对两组进行倾向评分匹配后也是如此。
在控制了几个社会人口学和临床参数后,巴西接受私人健康计划或公共系统资助的慢性 HD 患者的 1 年死亡风险相似。